These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 16273190)

  • 1. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
    Wixom CR; Albers EA; Weidner N
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
    Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
    Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R; Mulligan AM; Have C; O'Malley FP
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
    Mentrikoski MJ; Stoler MH
    Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays.
    Yau TK; Sze H; Soong IS; Hioe F; Khoo US; Lee AW
    Hong Kong Med J; 2008 Apr; 14(2):130-5. PubMed ID: 18382020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
    Bai YF; Ren GP; Wang B; Teng LS; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
    Mayr D; Heim S; Weyrauch K; Zeindl-Eberhart E; Kunz A; Engel J; Kirchner T
    Histopathology; 2009 Dec; 55(6):716-23. PubMed ID: 19922593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
    Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
    Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.